Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood marker may foretell kidney disease severity

NCT ID NCT05234463

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study investigates whether signs of complement activation in the blood can serve as a biomarker for the severity and progression of IgA nephropathy, a kidney disease. Researchers will follow 400 adults with biopsy-proven IgA nephropathy, including those with or without a kidney transplant, to see if elevated complement markers correlate with severe outcomes like rapid kidney function decline or end-stage kidney disease. The goal is to improve risk assessment and guide treatment decisions for this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If complement activation proves to be a reliable biomarker, it could help identify patients at higher risk of severe IgA nephropathy, enabling earlier and more personalized treatment.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to all patients, and the biomarker's predictive value remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2022

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with a histologically proven diagnosis of IgA nephropathy, with or without kidney transplantation history followed in the Nephrology Department of Strasbourg University Hospital.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients, male or female, with a biopsy proven IgA nephropathy. * Primitive and secondary forms can be included * Regardless of the date of diagnosis and the level of kidney function * With or without past of kidney transplantation * Followed in the Nephrology Department, Strasbourg University Hospital * Signed informed consent Exclusion Criteria: * Active or recent infectious or inflammatory syndrome (\<2 months), recent vaccination (\<2 months), ongoing acute humoral rejection treatment, treatment with plasma exchanges (\<2 months), current treatment with complement inhibitors * Impossibility of giving informed information (emergency situation, difficulties in understanding, etc.) * Subject under safeguard of justice, guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IgA nephropathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IgA nephropathy severity in kidney transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service de néphrologie

    RECRUITING

    Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.